Moleculin Biotech is a clinical-stage biopharmaceutical company focused on developing therapeutic candidates in oncology and, more broadly, against certain infectious diseases. Its positioning is based on a highly speculative pipeline-driven model with significant upside potential, typical of small-cap U.S. biotech names, where value depends primarily on clinical validation and regulatory milestones rather than recurring revenues.